Insider Selling: Liquidia Technologies, Inc. (NASDAQ:LQDA) CAO Sells $17,036.04 in Stock

Liquidia Technologies, Inc. (NASDAQ:LQDA) CAO Dana Boyle sold 1,193 shares of the stock in a transaction on Monday, July 14th. The shares were sold at an average price of $14.28, for a total value of $17,036.04. Following the sale, the chief accounting officer directly owned 187,168 shares in the company, valued at $2,672,759.04. This trade represents a 0.63% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website.

Liquidia Technologies Stock Up 2.9%

LQDA stock opened at $14.60 on Friday. Liquidia Technologies, Inc. has a one year low of $8.26 and a one year high of $19.41. The company has a debt-to-equity ratio of 2.08, a quick ratio of 2.91 and a current ratio of 2.93. The stock has a market capitalization of $1.25 billion, a P/E ratio of -9.24 and a beta of -0.01. The company has a 50 day moving average price of $14.88 and a two-hundred day moving average price of $14.48.

Liquidia Technologies (NASDAQ:LQDA) last released its quarterly earnings data on Thursday, May 8th. The company reported ($0.45) earnings per share for the quarter, missing the consensus estimate of ($0.42) by ($0.03). Liquidia Technologies had a negative net margin of 903.80% and a negative return on equity of 177.91%. The company had revenue of $3.12 million during the quarter, compared to analyst estimates of $3.23 million. As a group, sell-side analysts expect that Liquidia Technologies, Inc. will post -1.51 EPS for the current year.

Wall Street Analyst Weigh In

A number of brokerages have commented on LQDA. Needham & Company LLC reaffirmed a “buy” rating on shares of Liquidia Technologies in a research report on Monday, June 2nd. Wells Fargo & Company lifted their price objective on Liquidia Technologies from $23.00 to $25.00 and gave the company an “overweight” rating in a research note on Thursday, June 12th. Raymond James Financial lifted their price objective on Liquidia Technologies from $27.00 to $29.00 and gave the company a “strong-buy” rating in a research note on Friday, May 9th. Wall Street Zen upgraded Liquidia Technologies from a “sell” rating to a “hold” rating in a research note on Thursday, May 22nd. Finally, BTIG Research reiterated a “buy” rating on shares of Liquidia Technologies in a research note on Tuesday, May 27th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating, six have assigned a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $26.89.

Hedge Funds Weigh In On Liquidia Technologies

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Vanguard Group Inc. grew its position in shares of Liquidia Technologies by 3.4% during the 4th quarter. Vanguard Group Inc. now owns 3,557,296 shares of the company’s stock worth $41,834,000 after buying an additional 115,367 shares during the period. LM Advisors LLC bought a new stake in Liquidia Technologies during the 4th quarter valued at $25,948,000. Whitefort Capital Management LP grew its stake in shares of Liquidia Technologies by 16.8% in the 4th quarter. Whitefort Capital Management LP now owns 1,987,245 shares of the company’s stock worth $23,370,000 after acquiring an additional 285,220 shares in the last quarter. Vestal Point Capital LP raised its position in Liquidia Technologies by 17.3% in the fourth quarter. Vestal Point Capital LP now owns 1,760,000 shares of the company’s stock worth $20,698,000 after acquiring an additional 260,000 shares during the period. Finally, Geode Capital Management LLC raised its stake in Liquidia Technologies by 8.2% in the fourth quarter. Geode Capital Management LLC now owns 1,339,254 shares of the company’s stock valued at $15,753,000 after purchasing an additional 101,597 shares in the last quarter. 64.54% of the stock is owned by institutional investors.

About Liquidia Technologies

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).